Type I Interferon Signalling In Bacterial Infection
Funder
National Health and Medical Research Council
Funding Amount
$738,274.00
Summary
Infectious diseases are a leading cause of death in Australia. Activation of disease-fighting inflammasomes sets in motion rapid immune defenses against pathogens. In this project, we explore how cell-cell communication molecules known as type I interferons communicate with inflammasomes to achieve the best outcome in the body in response to deadly bacterial infection. Understanding how these signals communicate with one another could reveal new ways to fight infectious diseases.
Understanding Neuroinflammation In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,043,216.00
Summary
This project opens a new line of enquiry into the cellular signalling mechanisms involved in the progression of AD and establishes whether targeting the involvement of type-1 IFN signalling influences the evolution of AD. New and novel approaches are clearly required to treat AD. Importantly, we believe that neuroinflammation is common to all causes of dementia and targeting the neuroinflammatory pathways has much wider implications than targeting the primary causative pathway.
The Role Of Apoptotic Caspases In Regulating Type I Interferon Production
Funder
National Health and Medical Research Council
Funding Amount
$791,746.00
Summary
Type I interferons (IFNs) are potent anti-viral cytokines. Dysregulated type I IFN responses result in major pathologies, e.g., embryonic lethality and defects in tissue homeostasis. We have identified a novel molecular mechanism regulating IFN production that relies on the host’s own apoptotic caspases. We hypothesize that apoptotic caspases critically regulate IFN responses during the process of cell death, with implications for tissue homeostasis and host responses to infection.
Interferon Epsilon As A Novel Regulator Of Host-bacterial Interaction In Homeostasis, Infection And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$843,088.00
Summary
Gut infections are a leading cause of death worldwide and healthcare use in Australia. Inflammatory bowel disease (IBD) is incurable and affects 1/200 young Australians. Type I interferons (T1IFNs) are important to control gut infections and IBD by interacting with particular bacterial species in the gut. We discovered one T1IFN, IFNε, in human gut. It protects against models of IBD in mice. We will use mouse and human samples to find bacterial or interferon treatments for infections and/or IBD.
Controlling Neuroinflammation In Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$639,577.00
Summary
Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.
Characterization Of A Novel IFNbeta Signaling Axis Mediated Via IFNAR1
Funder
National Health and Medical Research Council
Funding Amount
$353,754.00
Summary
Type I interferons (IFNs) play an important role in regulating immune responses to pathogens and tumors and are used therapeutically. This project will investigate a novel IFN signaling axis that we have recently characterized that is mediated via the low affinity IFN receptor, IFNAR1. This signaling axis occurs independently of the high affinity IFN receptor IFNAR2 and contributes to lethality in a model of septic shock.
Targeting Cytokine Signalling In Systemic Lupus Erythematosus
Funder
National Health and Medical Research Council
Funding Amount
$917,626.00
Summary
Systemic lupus erythematosus is a disease where the immune system attacks normally healthy tissues. The spontaneous overproduction of signalling molecules called interferons in lupus plays an important role in the severity of the disease. We have found that two proteins, named Bcl6 and PLZF, are important in controlling the interferon response in lupus patients. We propose that identifying how these proteins act to control interferon will aid in developing new treatments for lupus.
Identifying Novel Regulators Of RNA Receptor Signalling To Modulate Viral Innate Immunity
Funder
National Health and Medical Research Council
Funding Amount
$312,034.00
Summary
Viruses elicit a rapid immune response upon infection that is crucial for controlling viral spread and disease. Human cells detect viral molecules to coordinate the the production of anti-viral proteins. The aim of this research is to identify new genes that are essential for controlling the initial immune response to viral infection. This research will help us understand how virus infection can be controlled appropriately, and may lead to the development of new anti-viral therapeutics.
The Role Of BAFF, Its Receptor TACI And Toll-like Receptors In Autoimmunity And Tolerance.
Funder
National Health and Medical Research Council
Funding Amount
$486,824.00
Summary
There are 2 types of immune cells, innate cells reacting broadly against microbial elements, and adaptive cells educated to remember pathogens and provide improved immune responses. Most treatments against lupus target the adaptive cells with mixed success. We have discovered a new mechanism driving lupus at the level of innate immunity. This proposal will identify molecular players driving this unappreciated form of lupus and validate new therapeutic targets.
Targeting CD40L(CD154) On Dendritic Cells For CD8 T Cell-mediated Immunity And Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$558,441.00
Summary
Killer T cells fight infection but also participate in transplant rejection. Activation of killer T cells often requires helper T cells. However, in the absence of helper cells, we have found an alternative pathway by which killer cells can be activated. We will explore this new pathway in enhancing vaccine responses and in modulating transoplant rejection.